Business Wire

Axial Therapeutics Raises $37.25 Million in Series C Financing to Advance its Pipeline of Gut-Targeted Small Molecule Drugs for Neurological Diseases and Disorders

WOBURN, Mass.--(BUSINESS WIRE)--Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological diseases, today announced the completion of ...
Business Wire

Axial Therapeutics Doses First Subjects in Global Phase 2b Clinical Trial for Irritability Associated with Autism Spectrum Disorder (ASD)

WOBURN, Mass.--(BUSINESS WIRE)--Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological conditions, today announced that the first ...